Cargando…

Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis

Background: Neoadjuvant therapy (NAT) represents a paradigm shift in the management of patients with pancreatic ductal adenocarcinoma (PDAC) with perceived benefits including a higher R0 rate. However, it is unclear whether NAT affects the sites and patterns of recurrence after surgery. This review...

Descripción completa

Detalles Bibliográficos
Autores principales: Ratnayake, Bathiya, Savastyuk, Alina Y., Nayar, Manu, Wilson, Colin H., Windsor, John A., Roberts, Keith, French, Jeremy J., Pandanaboyana, Sanjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408905/
https://www.ncbi.nlm.nih.gov/pubmed/32640720
http://dx.doi.org/10.3390/jcm9072132
_version_ 1783567940480663552
author Ratnayake, Bathiya
Savastyuk, Alina Y.
Nayar, Manu
Wilson, Colin H.
Windsor, John A.
Roberts, Keith
French, Jeremy J.
Pandanaboyana, Sanjay
author_facet Ratnayake, Bathiya
Savastyuk, Alina Y.
Nayar, Manu
Wilson, Colin H.
Windsor, John A.
Roberts, Keith
French, Jeremy J.
Pandanaboyana, Sanjay
author_sort Ratnayake, Bathiya
collection PubMed
description Background: Neoadjuvant therapy (NAT) represents a paradigm shift in the management of patients with pancreatic ductal adenocarcinoma (PDAC) with perceived benefits including a higher R0 rate. However, it is unclear whether NAT affects the sites and patterns of recurrence after surgery. This review seeks to compare sites and patterns of recurrence after resection between patients undergoing upfront surgery (US) or after NAT. Methods: The EMBASE, SCOPUS, PubMed, and Cochrane library databases were systematically searched to identify eligible studies that compare recurrence patterns between patients who had NAT (followed by resection) with those that had US. The primary outcome included site-specific recurrence. Results: 26 articles were identified including 4986 patients who underwent resection. Borderline resectable pancreatic cancer (BRPC, 47% 1074/2264) was the most common, followed by resectable pancreatic cancer (RPC 42%, 949/2264). The weighted overall recurrence rates were lower among the NAT group, 63.4% vs. 74% (US) (OR 0.67 (CI 0.52–0.87), p = 0.006). The overall weighted locoregional recurrence rate was lower amongst patients who received NAT when compared to US (12% vs. 27% OR 0.39 (CI 0.22–0.70), p = 0.004). In BRPC, locoregional recurrence rates improved with NAT (NAT 25.8% US 37.7% OR 0.62 (CI 0.44–0.87), p = 0.007). NAT was associated with a lower weighted liver recurrence rate (NAT 19.4% US 30.1% OR 0.55 (CI 0.34–0.89), p = 0.023). Lung and peritoneal recurrence rates did not differ between NAT and US cohorts (p = 0.705 and p = 0.549 respectively). NAT was associated with a significantly longer weighted mean time to first recurrence 18.8 months compared to US (15.7 months) (OR 0.18 (CI 0.05–0.32), p = 0.015). Conclusion: NAT was associated with lower overall recurrence rate and improved locoregional disease control particularly for those with BRPC. Although the burden of liver metastases was less, there was no overall effect upon distant metastatic disease.
format Online
Article
Text
id pubmed-7408905
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74089052020-08-13 Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis Ratnayake, Bathiya Savastyuk, Alina Y. Nayar, Manu Wilson, Colin H. Windsor, John A. Roberts, Keith French, Jeremy J. Pandanaboyana, Sanjay J Clin Med Article Background: Neoadjuvant therapy (NAT) represents a paradigm shift in the management of patients with pancreatic ductal adenocarcinoma (PDAC) with perceived benefits including a higher R0 rate. However, it is unclear whether NAT affects the sites and patterns of recurrence after surgery. This review seeks to compare sites and patterns of recurrence after resection between patients undergoing upfront surgery (US) or after NAT. Methods: The EMBASE, SCOPUS, PubMed, and Cochrane library databases were systematically searched to identify eligible studies that compare recurrence patterns between patients who had NAT (followed by resection) with those that had US. The primary outcome included site-specific recurrence. Results: 26 articles were identified including 4986 patients who underwent resection. Borderline resectable pancreatic cancer (BRPC, 47% 1074/2264) was the most common, followed by resectable pancreatic cancer (RPC 42%, 949/2264). The weighted overall recurrence rates were lower among the NAT group, 63.4% vs. 74% (US) (OR 0.67 (CI 0.52–0.87), p = 0.006). The overall weighted locoregional recurrence rate was lower amongst patients who received NAT when compared to US (12% vs. 27% OR 0.39 (CI 0.22–0.70), p = 0.004). In BRPC, locoregional recurrence rates improved with NAT (NAT 25.8% US 37.7% OR 0.62 (CI 0.44–0.87), p = 0.007). NAT was associated with a lower weighted liver recurrence rate (NAT 19.4% US 30.1% OR 0.55 (CI 0.34–0.89), p = 0.023). Lung and peritoneal recurrence rates did not differ between NAT and US cohorts (p = 0.705 and p = 0.549 respectively). NAT was associated with a significantly longer weighted mean time to first recurrence 18.8 months compared to US (15.7 months) (OR 0.18 (CI 0.05–0.32), p = 0.015). Conclusion: NAT was associated with lower overall recurrence rate and improved locoregional disease control particularly for those with BRPC. Although the burden of liver metastases was less, there was no overall effect upon distant metastatic disease. MDPI 2020-07-06 /pmc/articles/PMC7408905/ /pubmed/32640720 http://dx.doi.org/10.3390/jcm9072132 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ratnayake, Bathiya
Savastyuk, Alina Y.
Nayar, Manu
Wilson, Colin H.
Windsor, John A.
Roberts, Keith
French, Jeremy J.
Pandanaboyana, Sanjay
Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis
title Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis
title_full Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis
title_fullStr Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis
title_full_unstemmed Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis
title_short Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis
title_sort recurrence patterns for pancreatic ductal adenocarcinoma after upfront resection versus resection following neoadjuvant therapy: a comprehensive meta-analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408905/
https://www.ncbi.nlm.nih.gov/pubmed/32640720
http://dx.doi.org/10.3390/jcm9072132
work_keys_str_mv AT ratnayakebathiya recurrencepatternsforpancreaticductaladenocarcinomaafterupfrontresectionversusresectionfollowingneoadjuvanttherapyacomprehensivemetaanalysis
AT savastyukalinay recurrencepatternsforpancreaticductaladenocarcinomaafterupfrontresectionversusresectionfollowingneoadjuvanttherapyacomprehensivemetaanalysis
AT nayarmanu recurrencepatternsforpancreaticductaladenocarcinomaafterupfrontresectionversusresectionfollowingneoadjuvanttherapyacomprehensivemetaanalysis
AT wilsoncolinh recurrencepatternsforpancreaticductaladenocarcinomaafterupfrontresectionversusresectionfollowingneoadjuvanttherapyacomprehensivemetaanalysis
AT windsorjohna recurrencepatternsforpancreaticductaladenocarcinomaafterupfrontresectionversusresectionfollowingneoadjuvanttherapyacomprehensivemetaanalysis
AT robertskeith recurrencepatternsforpancreaticductaladenocarcinomaafterupfrontresectionversusresectionfollowingneoadjuvanttherapyacomprehensivemetaanalysis
AT frenchjeremyj recurrencepatternsforpancreaticductaladenocarcinomaafterupfrontresectionversusresectionfollowingneoadjuvanttherapyacomprehensivemetaanalysis
AT pandanaboyanasanjay recurrencepatternsforpancreaticductaladenocarcinomaafterupfrontresectionversusresectionfollowingneoadjuvanttherapyacomprehensivemetaanalysis